U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H23NO3S
Molecular Weight 333.445
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CIGLITAZONE

SMILES

CC3(COC1=CC=C(CC2SC(=O)NC2=O)C=C1)CCCCC3

InChI

InChIKey=YZFWTZACSRHJQD-UHFFFAOYSA-N
InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)

HIDE SMILES / InChI

Molecular Formula C18H23NO3S
Molecular Weight 333.445
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Ciglitazone, 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione, is a hypoglycemic agent and a thiazolidenedione derivative. Ciglitazone binds to the PPAR gamma receptor and possesses agonist activity. This drug was in clinical trials in Japan for the treatment Diabetes mellitus, but that study has been discontinued. Ciglitazone was able to decrease the production of vascular endothelial growth factor (VEGF) in an in vitro human granulosa cell model. That result together with the pivotal role of VEGF in ovarian hyperstimulation syndrome suggests that ciglitazone may have a high potential as a therapeutic agent.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P37231|||Q15179
Gene ID: 5468.0
Gene Symbol: PPARG
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Sources: DOI: 10.1016/j.jtumed.2016.02.001
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.5 μg/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIGLITAZONE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
3 μg/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIGLITAZONE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
138 μg × h/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIGLITAZONE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
93 μg × h/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CIGLITAZONE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
1998 Dec 3
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.
1999 Mar 26
Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line.
2000 Oct
Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.
2001 Apr 13
Arylhydrocarbon receptor (AhR) is involved in negative regulation of adipose differentiation in 3T3-L1 cells: AhR inhibits adipose differentiation independently of dioxin.
2001 Aug
Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements.
2001 Jun 22
Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
2001 May
Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.
2002 Feb
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
2002 Jul
Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929.
2002 Jul 15
Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma.
2002 Jun
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.
2002 Jun 21
Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors.
2003 Jan 15
PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase.
2003 Jul
15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism.
2003 Mar 7
Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection.
2004 Oct
Effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of retinoic acid-inducible gene-I in endothelial cells stimulated with lipopolysaccharide.
2005 Dec
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.
2005 May
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
2005 May 12
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
2005 May 15
Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition.
2006 Aug
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
2006 Feb 28
Involvement of PPARgamma in oxidative stress-mediated prostaglandin E(2) production in SZ95 human sebaceous gland cells.
2006 Jan
Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.
2007 May
Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells.
2007 May
Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
2007 May
Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells.
2007 Oct 1
Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.
2007 Sep
Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture.
2008 Mar
Effects of the mango components mangiferin and quercetin and the putative mangiferin metabolite norathyriol on the transactivation of peroxisome proliferator-activated receptor isoforms.
2008 May 14
Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes.
2009 Apr
Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro.
2010 Apr
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010 Dec
Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands.
2010 Nov 16
Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
2011 Aug
Chemical genomics profiling of environmental chemical modulation of human nuclear receptors.
2011 Aug
The use of rat lens explant cultures to study the mechanism of drug-induced cataractogenesis.
2012 Mar
Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway.
2013 Oct 5
Patents

Sample Use Guides

for Diabetes mellitus in Japan
Route of Administration: Oral
Human middle ear epithelial cell lines (HMEECs) with or without ciglitazone pre-treatment were exposed to cigarette smoke solution (CSS) in order to induce the inflammatory response. The suppressive effect of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2(COX-2), were evaluated using real-time polymerase chain reaction and Western blotting. Stimulation with CSS at 40 μg/ml for 6 h resulted in a 4.1-fold increase in the expression of TNF-α mRNA in the HMEECs. CSS-induced up-regulation of TNF-α mRNA was decreased by more than 2.8-fold in cells pre-treated with ciglitazone. The up-regulation of COX-2 mRNA and increased COX-2 protein expression induced by CSS were also inhibited by more than 3.7-fold with ciglitazone pre-treatment.
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:55:50 UTC 2023
Edited
by admin
on Sat Dec 16 15:55:50 UTC 2023
Record UNII
U8QXS1WU8G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CIGLITAZONE
INN   USAN  
USAN   INN  
Official Name English
(±)-5-(P-((1-METHYLCYCLOHEXYL)METHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-((1-METHYLCYCLOHEXYL)METHOXY)PHENYL)METHYL)-, (±)-
Systematic Name English
U-63287
Code English
CIGLITAZONE [USAN]
Common Name English
ADD-3878
Code English
U-63,287
Code English
ciglitazone [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98241
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
Code System Code Type Description
DRUG BANK
DB09201
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
FDA UNII
U8QXS1WU8G
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
EVMPD
SUB06260MIG
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
SMS_ID
100000081290
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
WIKIPEDIA
CIGLITAZONE
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
USAN
T-124
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
PUBCHEM
2750
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
MESH
C039671
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID0040757
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
NCI_THESAURUS
C72726
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
INN
5364
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
ChEMBL
CHEMBL7002
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
CHEBI
64227
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
CAS
74772-77-3
Created by admin on Sat Dec 16 15:55:51 UTC 2023 , Edited by admin on Sat Dec 16 15:55:51 UTC 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
TARGET -> AGONIST
Binding Assay
IC50
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY